US Bancorp DE Acquires 2,001 Shares of HealthEquity, Inc. $HQY

US Bancorp DE increased its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY) by 10.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,351 shares of the company’s stock after acquiring an additional 2,001 shares during the quarter. US Bancorp DE’s holdings in HealthEquity were worth $2,132,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of HQY. Invesco Ltd. increased its holdings in HealthEquity by 50.6% in the 1st quarter. Invesco Ltd. now owns 2,446,198 shares of the company’s stock valued at $216,171,000 after buying an additional 821,425 shares during the period. Nuveen LLC bought a new position in HealthEquity in the 1st quarter valued at about $53,076,000. Price T Rowe Associates Inc. MD increased its holdings in HealthEquity by 995.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 639,345 shares of the company’s stock valued at $56,500,000 after buying an additional 580,988 shares during the period. Westfield Capital Management Co. LP bought a new position in HealthEquity in the 1st quarter valued at about $49,787,000. Finally, Ameriprise Financial Inc. increased its holdings in HealthEquity by 148.1% in the 1st quarter. Ameriprise Financial Inc. now owns 669,939 shares of the company’s stock valued at $59,203,000 after buying an additional 399,897 shares during the period. 99.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

HQY has been the topic of several recent analyst reports. KeyCorp decreased their target price on shares of HealthEquity from $125.00 to $120.00 and set an “overweight” rating on the stock in a report on Wednesday, October 8th. Jefferies Financial Group lifted their price target on shares of HealthEquity from $130.00 to $134.00 and gave the company a “buy” rating in a report on Wednesday, September 3rd. Raymond James Financial reaffirmed a “strong-buy” rating and set a $120.00 price target (up from $115.00) on shares of HealthEquity in a report on Tuesday, July 8th. JPMorgan Chase & Co. lifted their price target on shares of HealthEquity from $125.00 to $126.00 and gave the company an “overweight” rating in a report on Wednesday, September 3rd. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of HealthEquity in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $121.31.

HealthEquity Stock Down 1.6%

Shares of NASDAQ HQY opened at $92.55 on Thursday. The company has a market capitalization of $7.97 billion, a P/E ratio of 56.09, a price-to-earnings-growth ratio of 1.35 and a beta of 0.47. HealthEquity, Inc. has a 52-week low of $74.07 and a 52-week high of $116.65. The company has a debt-to-equity ratio of 0.47, a quick ratio of 4.23 and a current ratio of 4.23. The company’s 50 day moving average price is $91.75 and its 200-day moving average price is $93.94.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Tuesday, September 2nd. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.92. The firm had revenue of $325.80 million for the quarter, compared to the consensus estimate of $320.68 million. HealthEquity had a net margin of 11.49% and a return on equity of 12.04%. HealthEquity has set its FY 2026 guidance at 3.740-3.91 EPS. Equities analysts forecast that HealthEquity, Inc. will post 2.32 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Michael Henry Fiore sold 1,781 shares of HealthEquity stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $88.21, for a total value of $157,102.01. Following the completion of the sale, the executive vice president owned 49,795 shares in the company, valued at $4,392,416.95. The trade was a 3.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Delano Ladd sold 6,000 shares of HealthEquity stock in a transaction on Friday, September 19th. The shares were sold at an average price of $94.11, for a total transaction of $564,660.00. Following the completion of the sale, the executive vice president owned 79,456 shares of the company’s stock, valued at $7,477,604.16. This represents a 7.02% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by insiders.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.